Asaf Danziger compensation by year
NovoCure Summary Compensation Table · all 9 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $651,272 | $698,439 | $692,675 | $702,295 | $781,868 | $876,086 | $830,649 | $756,093 | $763,782 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $1,144,000 | $587,505 | $1,155,020 | $6,946,850 | $0 | $0 | $0 | $0 |
| Option awards | $652,694 | $1,533,150 | $2,359,400 | $4,472,183 | $0 | $0 | $579,437 | $0 | $0 |
| Non-equity incentive | $0 | $643,668 | $644,266 | $693,139 | $934,607 | $0 | $584,220 | $507,742 | $508,338 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $276,483 | $292,331 | $286,448 | $293,970 | $293,379 | $303,197 | $284,645 | $257,191 | $266,968 |
| Total | $1,580,449 | $4,311,588 | $4,570,294 | $7,316,607 | $8,956,704 | $1,179,283 | $2,278,951 | $1,521,026 | $1,539,088 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NovoCure Ltd DEF 14A filed April 21, 2025, accession 0001645113-25-000005, and prior-year filings.
How this page was built: the NovoCure Ltd filed document, accession 0001645113-25-000005. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 100,142 | $1,495,120 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in NovoCure Ltd's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2024 proxy (filed April 21, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-30 | Grant or award | — | 268 | $11.15 | 416,742 |
| 2025-06-30 | Grant or award | — | 833 | $15.13 | 416,473 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
NovoCure’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Ashley Cordova | Chief Financial Officer | $6,091,704 |
| Frank Leonard | Executive Vice President, President Novocure US | $5,823,930 |
| Uri Weinberg | Chief Innovation Officer | $5,055,906 |
| Barak Ben-Arye | General Counsel | $4,799,381 |
| Asaf Danziger · this page | Chief Executive Officer | $1,539,088 |
Board service
NovoCure board · FY2021–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $811,594 | $11,920,000 | — | $340,278 | $13,071,872 |
| FY2024 | — | — | — | — | — |
| FY2022 | — | — | — | — | — |
| FY2021 | — | — | — | — | — |
Each year as the company reported it in NovoCure's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: NovoCure pays directors a $55,000 cash retainer and $375,000 in equity. As stated in NovoCure's FY2025 proxy.
The full NovoCure compensation record
free company briefThis page is one person within NovoCure's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the NovoCure proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NovoCure's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.